Uveitis Treatment Market Industry Analysis, Growth, Size, Share and Forecast to 2026

Uveitis is a combined condition of inflammation and swelling of the eyes. Uvea comprises of three parts Iris, ciliary body (small ring shape muscles behind iris and choroid), and choroid (it is the layer of tissue between retina and sclera), which decides eye color and helps eye in focusing and absorbing light. Uveitis can be caused by eye problems, autoimmune disease, HIV, multiple sclerosis, reactive arthritis, Kawasaki disease tuberculosis, and syphilis. Uveitis can affect people between the ages of 16 to 60 years, sometimes it may lead to permanent loss of vision. According to the National Center for Biotechnology Information (NCBI), uveitis counts for 10% to 15% of overall blindness. Treatments available for of uveitis include steroids, immunosuppressant, and monoclonal antibodies. Surgeries are performed in rare cases. Various pharmaceutical companies are working on R&D to launch new and effective medication for the treatment of uveitis, which is expected to boost the uveitis market.

Download PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1094

Research and development fuels the growth of uveitis treatment market

Several companies such as Pfizer Inc., pSivida Corp., and Novartis AG are investing in R&D to produce novel drug for the treatment of uveitis. There are few drugs already in pipeline such as Sirolimus, dexamethasone phosphate, rituximab, which will boost the uveitis treatment market. Increase in demand of generic drugs is also expected to support the growth of uveitis treatment market. Uveitis are caused by infections such as cat-scratch disease, herpes zoster, and ulcerative colitis. According to NCBI report, 17.4 to 52.4 cases per 100000 person every year takes place and it causes 2.8 -10% of legal blindness in the U.S annually. Corticosteroids are the most commonly used treatment for uveitis as compared to other drugs such as biologics, immunosuppressant. After corticosteroids antibiotics and monoclonal antibodies are mostly used for the treatment. Side effects of medication such as blurred vision, weight gain, insomnia, and increased appetite could be the major restraint for the growth of the uveitis market. Lack of awareness in emerging economies can lead to chronic eye disease and vision loss.

Speedy FDA approvals for uveitis treatment drugs to propel the market growth

A large number of new as well as established companies are focusing on development of drugs for the treatment of uveitis in various forms such as monoclonal antibodies, immunosuppressant, corticosteroids, anti-fungal agents, anti-viral agents, and others. FDA is focusing on speedy drug approval process as uveitis has serious ill effects leading to disorders such as glaucoma and permanent blindness. This creates a highly conducive environment for market players to invest in research and development activities to file for patents as well as develop generic biologics for treating this disorder. According to the Regulatory Affairs Professionals Society, FDA has approved around 38 generic drugs till July 2017.

Asia Pacific is expected to witness a significant growth in the global uveitis treatment market and this can be attributed to increasing number of regional players focusing on development of biologics for the treatment of uveitis. For instance, Santen Pharmaceuticals received U.S. FDA approval for its new drug in April 2017, for the treatment of non-infectious uveitis of the posterior segment.

Uveitis treatment market taxonomy

By Indication

Anterior uveitis,Intermediate uveitis,Posterior uveitis,Pan uveitis,.

By Cause

Infectious,Non infectious,.

By Condition


By Drug

Corticosteroids,Immunosuppressant,Monoclonal antibodies,Cycloplegic agents,Antibodies,Antiviral,Antifungals,Analgesics,.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

You May Also Like